

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets


(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 an...


Avacta still waiting on response from UK regulator over Covid test


(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 a...


IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"


Avacta sees Covid-19 tests driving earnings after reporting 2020 loss


(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 a...


IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial